The PCSK9 of NASH? Regeneron and Alnylam join forces to tackle a promising target for severe liver diseases
The Regeneron Genetics Center $REGN routinely sifts through a mountain of sequencing data. And every now and then, the researchers there will pan out a glittering finding that looks like it could rank right up there with PCSK9.
Here’s one.
This evening, in a study published in the New England Journal of Medicine, they are pointing to one such discovery that they believe has some big implications for severe liver diseases, including the Holy Grail of NASH. And without a logical antibody strategy to put into play — given an intracellular target in the spotlight — they’ve enlisted an experienced crew at Alnylam to bring their RNAi gene silencing platform into the game to find the most efficient way to provide the key to countering a raft of ailments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.